Literature DB >> 17627570

Botulinum toxin: pharmacology and clinical developments: a literature review.

R Hackett1, P C A Kam.   

Abstract

Botulinum toxin is used as first line therapy for some muscular disorders, and is efficacious in treating hypersecretory and some pain syndromes. When used appropriately it has a good safety profile. It has been evaluated in treating a number of conditions that as yet do not have obvious effective or beneficial treatment. With the greater acceptance and use of botulinum toxin therapy for cosmetic purposes, botulinum toxin use will increase. An understanding of the pharmacology, and potential adverse effects is essential for the physician when managing patients having or who would benefit from botulinum toxin therapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17627570     DOI: 10.2174/157340607781024438

Source DB:  PubMed          Journal:  Med Chem        ISSN: 1573-4064            Impact factor:   2.745


  12 in total

1.  Synthesis and evaluation of library of betulin derivatives against the botulinum neurotoxin A protease.

Authors:  Peter Šilhár; Sami Alakurtti; Kateřina Čapková; Feng Xiaochuan; Charles B Shoemaker; Jari Yli-Kauhaluoma; Kim D Janda
Journal:  Bioorg Med Chem Lett       Date:  2011-03-04       Impact factor: 2.823

2.  Identification of a Natural Product Antagonist against the Botulinum Neurotoxin Light Chain Protease.

Authors:  Lisa M Eubanks; Peter Silhár; Nicholas T Salzameda; Joseph S Zakhari; Feng Xiaochuan; Joseph T Barbieri; Charles B Shoemaker; Mark S Hixon; Kim D Janda
Journal:  ACS Med Chem Lett       Date:  2010       Impact factor: 4.345

3.  Injections of Clostridium botulinum neurotoxin A may cause thyroid complications in predisposed persons based on molecular mimicry with thyroid autoantigens.

Authors:  Edvina Gregoric; Jurji Avramovic Gregoric; Fabrizio Guarneri; Salvatore Benvenga
Journal:  Endocrine       Date:  2011-02       Impact factor: 3.633

4.  Impact of botulinum toxin A injection on esophageal anastomosis in a rabbit model.

Authors:  Yoshiko Usui; Shigeru Ono
Journal:  Pediatr Surg Int       Date:  2016-07-26       Impact factor: 1.827

5.  Synthesis/biological evaluation of hydroxamic acids and their prodrugs as inhibitors for Botulinum neurotoxin A light chain.

Authors:  Hajime Seki; Sabine Pellett; Peter Silhár; G Neil Stowe; Beatriz Blanco; Matthew A Lardy; Eric A Johnson; Kim D Janda
Journal:  Bioorg Med Chem       Date:  2013-12-08       Impact factor: 3.641

6.  Evaluation of adamantane hydroxamates as botulinum neurotoxin inhibitors: synthesis, crystallography, modeling, kinetic and cellular based studies.

Authors:  Peter Šilhár; Nicholas R Silvaggi; Sabine Pellett; Kateřina Čapková; Eric A Johnson; Karen N Allen; Kim D Janda
Journal:  Bioorg Med Chem       Date:  2012-12-20       Impact factor: 3.641

7.  The C-terminus of Botulinum A Protease Has Profound and Unanticipated Kinetic Consequences Upon the Catalytic Cleft.

Authors:  Peter Silhár; Matthew A Lardy; Mark S Hixon; Charles B Shoemaker; Joseph T Barbieri; Anjali K Struss; Jenny M Lively; Sacha Javor; Kim D Janda
Journal:  ACS Med Chem Lett       Date:  2012-12-23       Impact factor: 4.345

8.  Examination of α-exosite inhibitors against Botulinum neurotoxin A protease through structure-activity relationship studies of chicoric acid.

Authors:  Song Xue; Hajime Seki; Marek Remes; Peter Šilhár; Kim Janda
Journal:  Bioorg Med Chem Lett       Date:  2017-10-12       Impact factor: 2.823

Review 9.  Escherichia coli cytotoxic necrotizing factor 1 (CNF1): toxin biology, in vivo applications and therapeutic potential.

Authors:  Alessia Fabbri; Sara Travaglione; Carla Fiorentini
Journal:  Toxins (Basel)       Date:  2010-02-23       Impact factor: 4.546

10.  Differential characteristics of incobotulinumtoxinA and its use in the management of glabellar frown lines.

Authors:  Welf Prager
Journal:  Clin Pharmacol       Date:  2013-03-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.